Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com

RnRMarketResearch.com adds Nocturia – Pipeline Review, H2 2014 market research report of 31 pages to the Nocturia drugs industry and company profiles research collection of its business intelligence library.

Dallas, TX (PRWEB) November 22, 2014

Nocturia is defined by the International Continence Society (ICS) as the complaint that the individual has to wake at night one or more times for voiding. The report “Nocturia – Pipeline Review, H2 2014” provides comprehensive information on the therapeutic development for Nocturia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nocturia and special features on late-stage and discontinued projects. Complete Report is Available at http://www.rnrmarketresearch.com/nocturia-pipeline-review-h2-2014-market-report.html.

There are three ways in which nocturia can be caused: By problems of fluid balance, by neurological diseases affecting bladder control and by disorders of the lower urinary tract (LUT). Companies discussed in this Nocturia therapy Pipeline market report include Allergan, Inc., Drais Pharmaceuticals, Inc., Ferring International Center S.A., Sumitomo Dainippon Pharma Co., Ltd., Vantia Therapeutics. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Order a Purchase copy at http://www.rnrmarketresearch.com/contacts/purchase?rname=242176 .

Drugs profiled discussed in this Nocturia therapy Pipeline market report include (bromfenac + dexamethasone), dexamethasone acetate, LP-01309, PRO-155, Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology, Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis, Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders.

List of Table & Figures include in this reports are

List of Tables
Number of Products under Development for Nocturia, H2 2014
Number of Products under Development for Nocturia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Comparative Analysis by Late Stage Development, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Nocturia - Pipeline by Allergan, Inc., H2 2014
Nocturia - Pipeline by Drais Pharmaceuticals, Inc., H2 2014
Nocturia - Pipeline by Ferring International Center S.A., H2 2014
Nocturia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014
Nocturia - Pipeline by Vantia Therapeutics, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Nocturia - Dormant Projects, H2 2014

List of Figures
Number of Products under Development for Nocturia, H2 2014
Number of Products under Development for Nocturia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Top 10 Targets, H2 2014
Number of Products by Stage and Top 10 Targets, H2 2014
Number of Products by Top 10 Mechanism of Actions, H2 2014
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
Number of Products by Top 10 Routes of Administration, H2 2014
Number of Products by Stage and Top 10 Routes of Administration, H2 2014
Number of Products by Top 10 Molecule Types, H2 2014
Number of Products by Stage and Top 10 Molecule Types, H2 2014

Explore more reports on Urology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/urology-therapeutics.

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

For the original version on PRWeb visit: http://www.prweb.com/releases/nocturia-pipeline-review/h2-2014-market-report/prweb12342273.htm